Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B

Abstract

Starting antiviral therapy in IT phase is cost-effective compared with delaying the treatment until the active hepatitis phase in CHB patients, especially with increasing HCC risk, decreasing drug costs and consideration of productivity loss.